# of Displayed Technologies: 1 / 1


Categories

T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
  • College: OSU Wexner Medical Center
  • Inventors: Rubinstein, Mark
  • Licensing Officer: Willson, Christopher

Loading icon